Marinomed Biotech AG is an Austrian, science-based biotech company with a growing development pipeline and globally marketed therapeutics. The Company develops innovative patent-protected products in the therapeutic areas immunology and virology based on the platform Marinosolv® and the virus-blocking activity of iota-carrageenan. The Marinosolv® technology improves the solubility and bioavailability of hardly soluble compounds and is used to develop new therapeutics for autoreactive immune disorders. The virology segment includes Carragelose®-based over-the-counter (OTC) products to prevent and treat respiratory viral infections that are partnered in more than 40 countries. Marinomed also develops drugs for other serious viral infectious diseases based on iota-carrageenan. The Company is headquartered in Korneuburg, Austria, and is listed on the prime market of the Vienna Stock Exchange (VSE:MARI). https://www.marinomed.com/en/data-protection-declaration https://www.marinomed.com/en/legal-notice
View Top Employees from Marinomed Biotech AGWebsite | https://www.marinomed.com/en |
Revenue | $3 million |
Employees | 48 (44 on RocketReach) |
Founded | 2006 |
Phone | +43 2262 90300 |
Fax | +43 1 250774493 |
Technologies |
JavaScript,
HTML,
Twitter
+8 more
(view full list)
|
Industry | Biotechnology, Drug Stores & Pharmacies, Biopharma, Retail, Drug Discovery, Health Care, Science and Engineering, Medical, Product Design, Design, Therapeutics |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 32 Companies, NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies |
Looking for a particular Marinomed Biotech AG employee's phone or email?
The Marinomed Biotech AG annual revenue was $3 million in 2024.
Andreas Grassauer is the CEO of Marinomed Biotech AG.
44 people are employed at Marinomed Biotech AG.
The NAICS codes for Marinomed Biotech AG are [32, 32541, 3254, 325].
The SIC codes for Marinomed Biotech AG are [28, 283].